KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN G...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SYDNEY, Sept. 9, 2022 /PRNewswire-Asianet/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral pr...
Authors: LATEST ASIANET NEWS RELEASES